![ethyl pyrazolo[1,5-a]pyridine-2-carboxylate](https://static.cymitquimica.com/cas-image/498427-ethyl-pyrazolo-15-a-pyridine-2-carboxylate.png)
CAS: 80537-14-0 - ethyl pyrazolo[1,5-a]pyridine-2-carboxylate
Formula:C9H8N2O2
InChI:InChI=1/C9H8N2O2/c1-13-9(12)8-6-7-4-2-3-5-11(7)10-8/h2-6H,1H3
- Synonyms:
- 80537-14-0
- Methyl Pyrazolo[1,5-A]Pyridine-2-Carboxylate
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | Ethyl pyrazolo[1,5-a]pyridine-2-carboxylate REF: IN-DA005KMTCAS: 80537-14-0 | 95% | To inquire | Mon 16 Dec 24 |
 | Ethyl pyrazolo[1,5-a]pyridine-2-carboxylate REF: 10-F220298CAS: 80537-14-0 | 95.0% | To inquire | Fri 27 Dec 24 |
 | Pyrazolo[1,5-a]pyridine-2-carboxylic acid ethyl ester REF: 3D-FDA53714CAS: 80537-14-0 | Min. 95% | - - - | Discontinued product |
![Ethyl pyrazolo[1,5-a]pyridine-2-carboxylate](https://static.cymitquimica.com/products/IN/thumb/DA005KMT.jpg)
Ethyl pyrazolo[1,5-a]pyridine-2-carboxylate
CAS:80537-14-0
Formula:
C10H10N2O2
Purity:
95%
Color and Shape:
Solid
Molecular weight:
190.1986
Ref: IN-DA005KMT
| 100mg | 155.00 € | ||
| 250mg | 164.00 € |
Estimated delivery in United States, on Monday 16 Dec 2024
![Ethyl pyrazolo[1,5-a]pyridine-2-carboxylate](https://static.cymitquimica.com/products/10/thumb/F220298.jpg)
Ethyl pyrazolo[1,5-a]pyridine-2-carboxylate
CAS:80537-14-0
Purity:
95.0%
Molecular weight:
190.20199584960938
Ref: 10-F220298
| 100mg | To inquire | ||
| 250mg | To inquire |
Estimated delivery in United States, on Friday 27 Dec 2024
![Pyrazolo[1,5-a]pyridine-2-carboxylic acid ethyl ester](https://static.cymitquimica.com/products/3D/thumb/FDA53714.jpg)
Pyrazolo[1,5-a]pyridine-2-carboxylic acid ethyl ester
CAS:80537-14-0
Versatile small molecule scaffold
Formula:
C10H10N2O2
Purity:
Min. 95%
Molecular weight:
190.2 g/mol
Ref: 3D-FDA53714
| 1g | Discontinued | Request information | |
| 5g | Discontinued | Request information | |
| 100mg | Discontinued | Request information | |
| 250mg | Discontinued | Request information | |
| 500mg | Discontinued | Request information |
